Athira Pharma Inc
NASDAQ:ATHA
Income Statement
Earnings Waterfall
Athira Pharma Inc
Income Statement
Athira Pharma Inc
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(44)
|
(54)
|
(64)
|
(77)
|
(84)
|
(90)
|
(94)
|
(110)
|
(118)
|
(129)
|
(127)
|
(123)
|
(120)
|
(112)
|
(97)
|
(83)
|
(62)
|
(39)
|
|
| Selling, General & Administrative |
(13)
|
(19)
|
(21)
|
(27)
|
(31)
|
(31)
|
(33)
|
(32)
|
(33)
|
(34)
|
(33)
|
(31)
|
(27)
|
(27)
|
(26)
|
(25)
|
(23)
|
(19)
|
|
| Research & Development |
(30)
|
(35)
|
(43)
|
(50)
|
(53)
|
(59)
|
(61)
|
(68)
|
(75)
|
(85)
|
(94)
|
(94)
|
(94)
|
(85)
|
(71)
|
(54)
|
(35)
|
(20)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(10)
|
(10)
|
(10)
|
0
|
0
|
0
|
0
|
0
|
(4)
|
(4)
|
0
|
|
| Operating Income |
(44)
N/A
|
(54)
-24%
|
(64)
-18%
|
(77)
-20%
|
(84)
-9%
|
(90)
-8%
|
(94)
-5%
|
(110)
-17%
|
(118)
-7%
|
(129)
-9%
|
(127)
+2%
|
(123)
+3%
|
(120)
+3%
|
(112)
+7%
|
(97)
+13%
|
(83)
+14%
|
(62)
+25%
|
(39)
+37%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
(0)
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(10)
|
0
|
0
|
0
|
2
|
0
|
0
|
(2)
|
(4)
|
0
|
0
|
0
|
|
| Total Other Income |
5
|
8
|
9
|
9
|
5
|
6
|
8
|
6
|
10
|
9
|
8
|
7
|
6
|
5
|
4
|
3
|
2
|
2
|
|
| Pre-Tax Income |
(39)
N/A
|
(46)
-18%
|
(55)
-19%
|
(67)
-22%
|
(77)
-15%
|
(82)
-6%
|
(96)
-17%
|
(102)
-7%
|
(108)
-5%
|
(121)
-12%
|
(118)
+2%
|
(116)
+1%
|
(113)
+2%
|
(109)
+4%
|
(97)
+11%
|
(80)
+18%
|
(60)
+25%
|
(38)
+37%
|
|
| Net Income | |||||||||||||||||||
| Income from Continuing Operations |
(39)
|
(46)
|
(55)
|
(67)
|
(77)
|
(82)
|
(96)
|
(102)
|
(108)
|
(121)
|
(118)
|
(116)
|
(113)
|
(109)
|
(97)
|
(80)
|
(60)
|
(38)
|
|
| Net Income (Common) |
(39)
N/A
|
(46)
-18%
|
(55)
-19%
|
(67)
-22%
|
(77)
-15%
|
(82)
-6%
|
(96)
-17%
|
(102)
-7%
|
(108)
-5%
|
(121)
-12%
|
(118)
+2%
|
(116)
+1%
|
(113)
+2%
|
(109)
+4%
|
(97)
+11%
|
(80)
+18%
|
(60)
+25%
|
(38)
+37%
|
|
| EPS (Diluted) |
-10.47
N/A
|
-12.38
-18%
|
-14.85
-20%
|
-17.81
-20%
|
-20.52
-15%
|
-21.64
-5%
|
-25.34
-17%
|
-27.02
-7%
|
-28.35
-5%
|
-31.67
-12%
|
-30.95
+2%
|
-30.32
+2%
|
-29.56
+3%
|
-28.35
+4%
|
-25.19
+11%
|
-20.42
+19%
|
-15.31
+25%
|
-9.56
+38%
|
|